Upadacitinib: Mechanism of action, clinical, and translational science
Abstract Upadacitinib is a selective Janus kinase (JAK) inhibitor which is approved by the US Food and Drug Administration, the European Medicines Agency, as well as other agencies around the world for the treatment of several chronic inflammatory diseases, including rheumatic, dermatologic, and gas...
| Published in: | Clinical and Translational Science |
|---|---|
| Main Authors: | , , , , |
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-01-01
|
| Online Access: | https://doi.org/10.1111/cts.13688 |